We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Monitor glucose levels closely in patients with diabetes during direct-acting antiviral therapy for hepatitis C, particularly within the first 3 months of treatment, and modify diabetes medication or doses when necessary. Patients with diabetes may experience symptomatic hypoglycaemia if diabetic...
INR should be monitored closely during treatment of chronic hepatitis C with direct-acting antivirals in patients also receiving vitamin K antagonists (eg, warfarin), because of possible changes in liver function during treatment.
All patients should be screened for hepatitis B before starting treatment for chronic hepatitis C with direct-acting antiviral interferon-free regimens. Patients who are co-infected with hepatitis B and C viruses are at risk of hepatitis B reactivation, and should be...
List of Field Safety Notices from 30 October to 3 November 2023.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Neon Healthcare Ltd is recalling the specific batch mentioned in this notification as a precautionary measure.
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.